Publications in OpenAlex of which a co-author is affiliated to this organization
All publications | By field | By subfield
All publications [Next]
| Title | DOI |
|---|---|
| https://doi.org/10.1001/jamaneurol.2023.5319 | Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology |
| https://doi.org/10.1007/s00401-021-02275-6 | Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology |
| https://doi.org/10.1016/j.biopsych.2020.02.001 | The β-Secretase BACE1 in Alzheimer’s Disease |
| https://doi.org/10.3389/fneur.2015.00179 | A Practical Guide to Immunoassay Method Validation |
| https://doi.org/10.1093/brain/awac333 | Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease |
| https://doi.org/10.1038/s41398-020-01137-1 | Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer’s disease |
| https://doi.org/10.1002/acn3.274 | CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease |
| https://doi.org/10.1038/s41591-022-02074-w | Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer’s trial selection and disease monitoring |
| https://doi.org/10.15252/emmm.202012921 | Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Aβ pathology are detected |
| https://doi.org/10.1016/j.jalz.2013.01.010 | CSF biomarker variability in the Alzheimer's Association quality control program |
| https://doi.org/10.1038/s41591-022-01925-w | Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease |
| https://doi.org/10.2217/bmm.12.46 | Recommendations to Standardize Preanalytical Confounding Factors in Alzheimer’s and Parkinson’s Disease Cerebrospinal Fluid Biomarkers: An Update |
| https://doi.org/10.1016/j.jalz.2016.09.014 | Blood‐based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic |
| https://doi.org/10.1001/jamaneurol.2015.1285 | Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age |
| https://doi.org/10.1186/s13195-020-00682-7 | Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology |
| https://doi.org/10.1001/jamaneurol.2021.2293 | Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes |
| https://doi.org/10.1002/alz.12447 | Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease |
| https://doi.org/10.1002/alz.12841 | Plasma and CSF biomarkers in a memory clinic: Head‐to‐head comparison of phosphorylated tau immunoassays |
| https://doi.org/10.1038/s43587-023-00550-7 | Cerebrospinal fluid proteomics in patients with Alzheimer’s disease reveals five molecular subtypes with distinct genetic risk profiles |
| https://doi.org/10.1186/s13195-021-00939-9 | Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231 |
| https://doi.org/10.1016/j.ebiom.2022.103836 | Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease |
| https://doi.org/10.1016/j.jalz.2019.03.009 | Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease |
| https://doi.org/10.1038/nrneurol.2014.232 | Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases |
| https://doi.org/10.1016/j.nbd.2020.105086 | How specific are the conformation-specific α-synuclein antibodies? Characterization and validation of 16 α-synuclein conformation-specific antibodies using well-characterized preparations of α-synuclein monomers, fibrils and oligomers with distinct structures and morphology |
| https://doi.org/10.1016/j.jalz.2015.05.012 | C‐terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer's disease |
| https://doi.org/10.1111/jnc.14809 | Parkinson’s disease biomarkers based on α‐synuclein |
| https://doi.org/10.1016/j.trci.2019.11.002 | Synaptic biomarkers in CSF aid in diagnosis, correlate with cognition and predict progression in MCI and Alzheimer's disease |
| https://doi.org/10.1186/s13195-017-0276-4 | Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer’s disease core biomarkers in Lewy body disorders and Alzheimer’s dementia |
| https://doi.org/10.1093/brain/awv199 | Alzheimer’s disease cerebrospinal fluid biomarker in cognitively normal subjects |
| https://doi.org/10.1016/j.cca.2016.05.014 | CSF Aβ1–42 – an excellent but complicated Alzheimer's biomarker – a route to standardisation |
| https://doi.org/10.1212/wnl.0000000000012727 | Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays |
| https://doi.org/10.1016/j.jalz.2018.05.008 | The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review |
| https://doi.org/10.3233/jad-2012-120361 | Risk of Alzheimer's Disease Biological Misdiagnosis Linked to Cerebrospinal Collection Tubes |
| https://doi.org/10.1016/j.ymeth.2012.03.023 | Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer’s disease |
| https://doi.org/10.1186/s13195-020-00728-w | Comparison of ELISA- and SIMOA-based quantification of plasma Aβ ratios for early detection of cerebral amyloidosis |
| https://doi.org/10.1002/ana.26308 | Plasma p‐tau231, p‐tau181, PET Biomarkers, and Cognitive Change in Older Adults |
| https://doi.org/10.3389/fnagi.2018.00138 | Relevance of Aβ42/40 Ratio for Detection of Alzheimer Disease Pathology in Clinical Routine: The PLMR Scale |
| https://doi.org/10.2217/bmm.14.105 | The Utility of α-Synuclein as Biofluid Marker in Neurodegenerative Diseases: a Systematic Review of The Literature |
| https://doi.org/10.1002/dad2.12285 | Differential diagnostic performance of a panel of plasma biomarkers for different types of dementia |
| https://doi.org/10.1038/s41598-021-89004-x | Highly specific and ultrasensitive plasma test detects Abeta(1–42) and Abeta(1–40) in Alzheimer’s disease |
| https://doi.org/10.1186/s12883-017-0945-8 | Neurogranin and tau in cerebrospinal fluid and plasma of patients with acute ischemic stroke |
| https://doi.org/10.1016/j.ebiom.2022.103837 | Comparing tau status determined via plasma pTau181, pTau231 and [18F]MK6240 tau-PET |
| https://doi.org/10.1186/s40035-019-0181-9 | Effect of the micro-environment on α-synuclein conversion and implication in seeded conversion assays |
| https://doi.org/10.1186/s13195-022-01011-w | Diagnostic value of serum versus plasma phospho-tau for Alzheimer’s disease |
| https://doi.org/10.1161/strokeaha.118.022317 | C-Reactive Protein, Plasma Amyloid-β Levels, and Their Interaction With Magnetic Resonance Imaging Markers |
| https://doi.org/10.1038/s41531-022-00388-7 | Revisiting the specificity and ability of phospho-S129 antibodies to capture alpha-synuclein biochemical and pathological diversity |
| https://doi.org/10.1002/alz.14508 | The Alzheimer's Association Global Biomarker Standardization Consortium (GBSC) plasma phospho‐tau Round Robin study |
| https://doi.org/10.1373/clinchem.2017.283028 | Neurogranin as Cerebrospinal Fluid Biomarker for Alzheimer Disease: An Assay Comparison Study |
| https://doi.org/10.1186/s40478-019-0682-x | The elusive tau molecular structures: can we translate the recent breakthroughs into new targets for intervention? |
| https://doi.org/10.1002/alz.12145 | First amyloid β1‐42 certified reference material for re‐calibrating commercial immunoassays |
| https://doi.org/10.1002/alz.12759 | Menopause hormone therapy significantly alters pathophysiological biomarkers of Alzheimer's disease |
| https://doi.org/10.1186/s13195-023-01212-x | Synaptic biomarkers in the cerebrospinal fluid associate differentially with classical neuronal biomarkers in patients with Alzheimer’s disease and frontotemporal dementia |
| https://doi.org/10.1515/cclm-2015-0733 | Assessing the commutability of reference material formats for the harmonization of amyloid-β measurements |
| https://doi.org/10.1016/j.mcpro.2023.100629 | Methods to Discover and Validate Biofluid-Based Biomarkers in Neurodegenerative Dementias |
| https://doi.org/10.1002/ana.26610 | Decreased Cerebrospinal Fluid Amyloid β 38, 40, 42, and 43 Levels in Sporadic and Hereditary Cerebral Amyloid Angiopathy |
| https://doi.org/10.1002/dad2.12242 | The global Alzheimer's Association round robin study on plasma amyloid β methods |
| https://doi.org/10.1186/s12974-023-02796-9 | Neuroinflammatory CSF biomarkers MIF, sTREM1, and sTREM2 show dynamic expression profiles in Alzheimer’s disease |
| https://doi.org/10.3233/jad-220318 | A Combination of Neurofilament Light, Glial Fibrillary Acidic Protein, and Neuronal Pentraxin-2 Discriminates Between Frontotemporal Dementia and Other Dementias |
| https://doi.org/10.1002/dad2.12375 | Plasma p‐tau181/Aβ 1‐42 ratio predicts Aβ‐PET status and correlates with CSF‐p‐tau181/Aβ 1‐42 and future cognitive decline |
| https://doi.org/10.1093/braincomms/fcae162 | Plasma pTau181 and pTau217 predict asymptomatic amyloid accumulation equally well as amyloid PET |
| https://doi.org/10.1186/s13195-024-01630-5 | Analytical and clinical performance of eight Simoa® and Lumipulse® assays for automated measurement of plasma p-tau181 and p-tau217 |
| https://doi.org/10.1186/s13195-024-01620-7 | Post hoc analysis of ADAMANT, a phase 2 clinical trial of active tau immunotherapy with AADvac1 in patients with Alzheimer’s disease, positive for plasma p-tau217 |
| https://doi.org/10.1186/s13195-025-01762-2 | Influence of co-pathology on CSF and plasma synaptic markers SNAP25 and VAMP2 in Alzheimer’s disease and Parkinson’s disease |
| https://doi.org/10.1016/j.aca.2018.02.011 | Digital ELISA for the quantification of attomolar concentrations of Alzheimer's disease biomarker protein Tau in biological samples |
| https://doi.org/10.3233/jad-160286 | Optimized Standard Operating Procedures for the Analysis of Cerebrospinal Fluid Aβ42 and the Ratios of Aβ Isoforms Using Low Protein Binding Tubes |
| https://doi.org/10.2217/bmm.12.39 | Reference Measurement Procedures for Alzheimer’s Disease Cerebrospinal Fluid Biomarkers: Definitions and Approaches With Focus on Amyloid β42 |
| https://doi.org/10.1016/j.jalz.2017.01.010 | How to handle adsorption of cerebrospinal fluid amyloid β (1–42) in laboratory practice? Identifying problematic handlings and resolving the issue by use of the Aβ42/Aβ40 ratio |
| https://doi.org/10.1002/mds.27090 | A user's guide for α‐synuclein biomarker studies in biological fluids: Perianalytical considerations |
| https://doi.org/10.1089/neu.2013.2964 | Monitoring of β-Amyloid Dynamics after Human Traumatic Brain Injury |
| https://doi.org/10.3233/jad-170458 | Plasma Amyloid-β Levels, Cerebral Small Vessel Disease, and Cognition: The Rotterdam Study |
| https://doi.org/10.1111/jnc.14569 | Antibody‐based methods for the measurement of α‐synuclein concentration in human cerebrospinal fluid – method comparison and round robin study |
| https://doi.org/10.1373/clinchem.2011.178368 | Cerebrospinal Fluid Collection Tubes: A Critical Issue for Alzheimer Disease Diagnosis |
| https://doi.org/10.3233/jad-190533 | Ultrasensitive Detection of Plasma Amyloid-β as a Biomarker for Cognitively Normal Elderly Individuals at Risk of Alzheimer’s Disease |
| https://doi.org/10.3233/jad-160227 | The Cerebrospinal Fluid Neurogranin/BACE1 Ratio is a Potential Correlate of Cognitive Decline in Alzheimer’s Disease |
| https://doi.org/10.1186/s13195-018-0395-6 | Plasma amyloid-β levels, cerebral atrophy and risk of dementia: a population-based study |
| https://doi.org/10.1186/s13195-015-0159-5 | Diagnostic value of cerebrospinal fluid Aβ ratios in preclinical Alzheimer’s disease |
| https://doi.org/10.1186/s13195-020-00655-w | CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimer’s disease |
| https://doi.org/10.1186/s40478-015-0195-1 | TDP-43 as a possible biomarker for frontotemporal lobar degeneration: a systematic review of existing antibodies |
| https://doi.org/10.3233/jad-160298 | Performance Evaluation of an Automated ELISA System for Alzheimer’s Disease Detection in Clinical Routine |
| https://doi.org/10.1016/j.jalz.2016.09.005 | Prevention of tau increase in cerebrospinal fluid of APP transgenic mice suggests downstream effect of BACE1 inhibition |
| https://doi.org/10.3233/jad-160766 | Memory Correlates of Alzheimer’s Disease Cerebrospinal Fluid Markers: A Longitudinal Cohort Study |
| https://doi.org/10.1186/s13195-020-00686-3 | β-Secretase1 biological markers for Alzheimer’s disease: state-of-art of validation and qualification |
| https://doi.org/10.1186/s13024-017-0152-5 | Ex vivo 18O-labeling mass spectrometry identifies a peripheral amyloid β clearance pathway |
| https://doi.org/10.1016/j.neurobiolaging.2015.05.003 | Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study |
| https://doi.org/10.1161/strokeaha.117.019810 | Plasma Aβ (Amyloid-β) Levels and Severity and Progression of Small Vessel Disease |
| https://doi.org/10.1515/cclm-2018-0147 | Commutability of the certified reference materials for the standardization of β-amyloid 1-42 assay in human cerebrospinal fluid: lessons for tau and β-amyloid 1-40 measurements |
| https://doi.org/10.3233/jad-170564 | Relation of Odor Identification with Alzheimer’s Disease Markers in Cerebrospinal Fluid and Cognition |
| https://doi.org/10.3233/jad-170128 | Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer’s Disease Pathology Between Three Independent Assay Platforms |
| https://doi.org/10.1016/j.jalz.2019.07.001 | Brain Aβ load association and sexual dimorphism of plasma BACE1 concentrations in cognitively normal individuals at risk for AD |
| https://doi.org/10.1002/mds.28774 | Cellular Prion Protein Mediates α‐Synuclein Uptake, Localization, and Toxicity In Vitro and In Vivo |
| https://doi.org/10.1002/acn3.51553 | Phospho‐specific plasma p‐tau181 assay detects clinical as well as asymptomatic Alzheimer's disease |
| https://doi.org/10.1159/000489847 | Neurogranin and BACE1 in CSF as Potential Biomarkers Differentiating Depression with Cognitive Deficits from Early Alzheimer’s Disease: A Pilot Study |
| https://doi.org/10.3390/ijms23137221 | A Novel Neurofilament Light Chain ELISA Validated in Patients with Alzheimer’s Disease, Frontotemporal Dementia, and Subjective Cognitive Decline, and the Evaluation of Candidate Proteins for Immunoassay Calibration |
| https://doi.org/10.1007/s12035-018-1313-4 | Cerebrospinal Fluid Total and Phosphorylated α-Synuclein in Patients with Creutzfeldt–Jakob Disease and Synucleinopathy |
| https://doi.org/10.2217/bmm.12.44 | Analytical Aspects of Molecular Alzheimer’s Disease Biomarkers |
| https://doi.org/10.1016/j.trci.2018.10.003 | Cerebrospinal fluid neurogranin/β‐site APP‐cleaving enzyme 1 predicts cognitive decline in preclinical Alzheimer's disease |
| https://doi.org/10.1038/s41514-023-00114-4 | Elevated plasma sclerostin is associated with high brain amyloid-β load in cognitively normal older adults |
| https://doi.org/10.1002/ana.26048 | Onset of Preclinical Alzheimer Disease in Monozygotic Twins |
| https://doi.org/10.3390/ijms22062931 | Plasma Amyloid-Beta Levels in a Pre-Symptomatic Dutch-Type Hereditary Cerebral Amyloid Angiopathy Pedigree: A Cross-Sectional and Longitudinal Investigation |
| https://doi.org/10.3233/jad-150953 | Diagnostic Impact of Cerebrospinal Fluid Biomarker (Pre-)Analytical Variability in Alzheimer’s Disease |